Electrophysiological consequences of acute mobocertinib exposure in isolated rat and guinea-pig hearts and transfected cell lines.

Background: Mobocertinib is a first-in-class oral epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor approved for NSCLC with EGFR exon 20 insertions. Clinical trials indicate a signal for QT prolongation and heart failure, but the underlying mechanisms remain undefined. We used ex-vivo hearts and transfected cell lines to determine direct, acute electrophysiological consequences of mobocertinib in animal models.